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To investigate to what extent asymptomatic vs symptomatic 
prenatal Zika virus infections contribute to birth defects, we 
identified 3 prospective and 8 retrospective studies. The ratio 
varied greatly in the retrospective studies, most likely due to 
recruitment and recall bias. The prospective studies revealed 
a ratio of 1:1 for asymptomatic vs symptomatic maternal Zika 
infections resulting in adverse fetal outcomes.
Keywords. asymptomatic prenatal infection; congenital 
Zika syndrome; maternal infection; microcephaly; Zika.
 
Ever since the causal relationship between prenatal Zika virus 
(ZIKV) infection and microcephaly (and other serious brain 
anomalies) was established, the research focus has been on 
defining the full spectrum of defects caused by prenatal Zika 
virus infection, determining the relative and absolute risks of 
adverse outcomes among fetuses whose mothers were infected 
at different times during pregnancy and factors associated with 
adverse fetal outcomes [1]. An additional important research 
question is whether asymptomatic infections during pregnancy 
can also lead to congenital Zika syndrome (CZS), and the extent 
of this risk in comparison with symptomatic prenatal ZIKV 
infections. Based on a seroprevalence study in Yap Island, an 
asymptomatic-to-symptomatic ratio of 4:1 has been postulated 
in the general population [2]. However, this ratio was derived 
from nonspecific serological assays. Furthermore, such ratios 
may vary in different settings. For example, for dengue virus 
infections, another flavivirus transmitted by the same vector, 
asymptomatic-to-symptomatic ratios depend on age and viral 
virulence [3]. Pregnancy may also be associated with more 
clinical manifestations than reported in the general popula-
tion. Knowing the proportion of asymptomatic ZIKV infection 
in pregnant women, and the extent to which asymptomatic 
ZIKV infections lead to birth defects, is critical to understand-
ing the evolving epidemiology, selecting the best diagnostic 
approach in pregnant women, and informing vaccine develop-
ment. Setting up sufficiently large prospective cohort studies 
of pregnant women living or visiting countries during a Zika 
epidemic will be the best study design to accurately determine 
these proportions. Indeed, such studies are being funded by the 
National Institutes of Health/National Institute of Allergy and 
Infectious Diseases (https://www.nichd.nih.gov/news/releases/
Pages/zika_zip_06202016.aspx) and the European Commission 
[4], but definitive answers will not be able for another couple of 
years. In the absence of such results, we did a literature review to 
assess whether asymptomatic ZIKV infection during pregnancy 
is associated with CZS/microcephaly and to estimate the risk.
THE STUDY
Using the search terms “Zika” AND/OR “pregnancy” AND/
OR “microcephaly,” we identified 898 papers between 1947 and 
September 2017. We reviewed all titles and abstracts of publica-
tions and selected those articles that fulfilled the following eligibil-
ity criteria: original articles, birth outcomes from pregnant women 
with prenatal laboratory-confirmed ZIKV infection where clinical 
symptoms and the absence of clinical symptoms were reported. 
Eligible study designs were case series, case-control studies (in 
which the case was congenital Zika syndrome or microcephaly 
and presence or absence of symptoms during pregnancy was 
described), prospective studies following up returning travelers, 
and cohort studies. We excluded all studies where women were 
recruited only because of rash or other symptoms. We identified 
11 articles published from 2016 to 2017 conducted in 3 countries 
(Brazil, Colombia, and the United States) that fulfilled our inclu-
sion criteria. Using a standardized tool, we extracted the follow-
ing information: study design, year of publication, study location, 
period of study, study population, clinical symptoms in mothers, 
laboratory confirmation of ZIKV infection in mothers, adverse 
fetal outcome, and frequency of such outcomes in neonates.
Table  1 shows that the studies can be classified into those 
that recruit pregnant women and prospectively ascertain fetal 
outcomes [5–7] and those studies that recruit neonates with 
CZS or microcephaly and establish retrospectively whether 
the mother had symptoms compatible with a ZIKV infection 
[8–15]. The US cohort of pregnant women with laboratory-con-
firmed ZIKV infections offered the highest quality of evidence 
as the study was prospective in nature; women were enrolled 
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during pregnancy without prior knowledge about birth out-
come, which minimizes recall bias for “Zika-like symptoms” 
compared with retrospective case-control studies and case 
series [5–7]. In the 3 prospective studies reporting on 442 [5] 
to 2549 [7] completed pregnancies, the proportion of sympto-
matic maternal ZIKV infections ranged from 38% to 61%. In 
the first report, 6% of asymptomatic and equally 6% of symp-
tomatic maternal ZIKV infections resulted in CZS [5]; in the 
second report, 5% of women were symptomatic and 4% were 
asymptomatic [6]; and in the most recent report, 5% of women 
were symptomatic and 7% were asymptomatic [7]. In other 
words, the ratio of asymptomatic to symptomatic ZIKV infec-
tions resulting in adverse fetal outcomes is about 1:1. Among 
the completed 2549 pregnancies, there was no difference in the 
percentage of birth defects (between symptomatic and asymp-
tomatic women) in the subgroup of laboratory-confirmed Zika 
infection [7].
The retrospective studies also consistently found that a sub-
stantial proportion of mothers of neonates with CZS reported 
no symptoms and so presumably had an asymptomatic prena-
tal ZIKV infection; however, the proportion of symptomatic vs 
asymptomatic women varied greatly between studies. This varia-
tion can partially be explained by the case definition: Some stud-
ies considered fever and at least 1 additional sign or symptom; 
in other studies, the case definition included only 1 symptom 
(usually rash). Another variation presented was the definition 
of the outcome. In some case series, all the mothers had labo-
ratory-confirmed Zika infection during their pregnancy [9]; in 
other studies, the case definition was based on brain imaging 
consistent with ZIKV infection [11]. An additional explanation 
is recall bias and recruitment bias that would favor a history of 
rash or other symptoms compatible with ZIKV disease. In the 
retrospective studies, the proportion of CZS as a result of symp-
tomatic maternal ZIKV infection ranged from 88.9% [10] to 
34%, translating into a ratio of symptomatic-to-asymptomatic 
maternal infections between 5:1 and 1:2.
CONCLUSIONS
This review documents that asymptomatic prenatal ZIKV 
infection can result in CZS. The retrospective studies (case-con-
trol and case series) showed a variable risk, and this variation 
reflects a combination of recruitment bias, recall bias, and vary-
ing case definitions. Prospective cohort studies are less affected 
by such bias, and the only published cohort studies to date are 
based on the US Zika Pregnancy and Infant Registry, which 
reported roughly similar numbers of CZS in neonates born to 
women with symptomatic and asymptomatic ZIKV infection.
Our findings have several implications. First, the ratio of 
asymptomatic-to-symptomatic infections in pregnancy appears 
to be lower in pregnant travelers returning to the United States 
compared with the population-based seroprevalence study on 
Yap Island, although recruitment bias toward symptomatic 
women may have played a role in the higher proportion of 
symptomatic infections seen in the US study. Second, it high-
lights that surveillance of women based on rash or other symp-
toms is not sufficient, and screening all pregnant women for 
ZIKV exposure is necessary in areas or countries where ZIKV 
is circulating. Taking into account that currently available diag-
nostics for ZIKV are suboptimal and hence may miss maternal 
ZIKV infections, birth defect surveillance for CZS needs to be 
strengthened. Third, given the low viremia levels, more sensi-
tive diagnostic tools are urgently needed to improve maternal 
sceening. Fourth, as asymptomatic infections are likely associ-
ated with lower viremia, our findings suggest that even low lev-
els of viremia could lead to CZS. A high bar is hence required 
for Zika vaccine development, possibly necessitating a vaccine 
that achieves complete reduction or prevention of viremia, for 
example, sterilizing immunity. The demonstration of a clinical 
benefit of a vaccine is usually based on a clinical end point. Our 
findings would justify selecting ZIKV infection rather than 
ZIKV disease as a clinical end point. However, the disadvantage 
of such an end point is the need for frequent sampling to detect 
asymptomatic infections, confounded by the limitations of 
current diagnostic assays. Perhaps protection against infection 
could be studied in at least a subset of an efficacy trial where 
the primary end point would be clinical ZIKV disease. Lastly, 
the ratio of asymptomatic-to-symptomatic infections was best 
described in the US cohort but needs to be confirmed by larger 
prospective cohort studies in endemic countries.
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